| 11/16/2026 7:33 AM | Clearmind Medicine (1892500) Subject Iroquois Capital Management, LLC (1481867) Filed by | Form SCHEDULE 13G/A | |
| 11/16/2026 7:24 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/10/2026 6:37 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/27/2026 8:33 PM | Clearmind Medicine (1892500) Subject Gainor Lewis Berray (2161378) Filed by | Form SCHEDULE 13G | |
| 10/27/2026 7:24 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/16/2026 3:01 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/13/2026 5:16 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/08/2026 6:55 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/07/2026 7:41 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/30/2026 3:30 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/23/2026 7:00 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Get the Latest News and Ratings for CMND and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Clearmind Medicine and its competitors with MarketBeat's FREE daily newsletter.
|
| 09/17/2026 3:00 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/14/2026 5:08 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/10/2026 3:05 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/08/2026 6:43 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/04/2026 6:35 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/02/2026 3:01 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/01/2026 7:01 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/24/2026 3:00 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/12/2026 9:46 AM | Clearmind Medicine (1892500) Subject Iroquois Capital Management, LLC (1481867) Filed by | Form SCHEDULE 13G/A | |
| 08/11/2026 3:01 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/03/2026 7:12 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/30/2026 3:01 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/20/2026 3:00 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/17/2026 3:01 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/16/2026 12:39 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/13/2026 3:01 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/10/2026 3:00 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/07/2026 3:01 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/29/2026 7:11 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/22/2026 7:08 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/21/2026 11:15 PM | Clearmind Medicine (1892500) Filer | Form EFFECT | |
| 06/18/2026 4:05 PM | Clearmind Medicine (1892500) Issuer HRT FINANCIAL LP (1475597) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/18/2026 7:11 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/17/2026 3:42 PM | Clearmind Medicine (1892500) Issuer HRT FINANCIAL LP (1475597) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/16/2026 8:19 AM | Clearmind Medicine (1892500) Issuer HRT FINANCIAL LP (1475597) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/16/2026 6:35 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/15/2026 4:09 PM | Clearmind Medicine (1892500) Filer | Form POS AM | |
| 06/15/2026 3:01 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/12/2026 3:19 PM | Clearmind Medicine (1892500) Issuer HRT FINANCIAL LP (1475597) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 05/29/2026 7:35 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Your free book is about to disappear (Ad) Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link.
He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. Download the Safe Trade Options Formula book for free before access closes |
| 05/26/2026 7:30 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/19/2026 5:51 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/19/2026 5:21 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/18/2026 3:05 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/15/2026 3:15 PM | Capitalink Ltd. (2036836) Filed by Clearmind Medicine (1892500) Subject | Form SCHEDULE 13G/A | |
| 05/15/2026 3:15 PM | Clearmind Medicine (1892500) Subject L.I.A. Pure Capital Ltd (1749628) Filed by | Form SCHEDULE 13G/A | |
| 05/12/2026 8:27 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/07/2026 11:15 PM | Clearmind Medicine (1892500) Filer | Form EFFECT | |
| 05/05/2026 7:53 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/30/2026 3:21 PM | Clearmind Medicine (1892500) Filer | Form F-3 Registration statement for securities of certain foreign private issuers | |
| 04/27/2026 6:45 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/21/2026 5:57 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/20/2026 4:18 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/20/2026 3:05 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/15/2026 8:15 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/15/2026 6:00 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/14/2026 3:01 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/14/2026 7:23 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/30/2026 11:15 PM | Clearmind Medicine (1892500) Filer | Form EFFECT | |
| 03/30/2026 11:15 PM | Clearmind Medicine (1892500) Filer | Form EFFECT | |
| 03/30/2026 8:27 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/27/2026 6:40 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/25/2026 3:15 PM | Clearmind Medicine (1892500) Filer | Form POS AM | |
| 03/25/2026 3:15 PM | Clearmind Medicine (1892500) Filer | Form POS AM | |
| 03/19/2026 3:01 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/17/2026 8:16 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/16/2026 10:12 AM | Clearmind Medicine (1892500) Subject L.I.A. Pure Capital Ltd (1749628) Filed by | Form SCHEDULE 13G/A | |
| 03/16/2026 9:17 AM | Capitalink Ltd. (2036836) Filed by Clearmind Medicine (1892500) Subject | Form SCHEDULE 13G/A | |
| 03/13/2026 6:46 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/12/2026 3:16 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/11/2026 3:01 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/10/2026 8:29 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/09/2026 3:30 PM | Clearmind Medicine (1892500) Subject Daniel Nissim (2092834) Filed by | Form SCHEDULE 13G/A | |
| 03/04/2026 8:01 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/26/2026 11:15 PM | Clearmind Medicine (1892500) Filer | Form EFFECT | |
| 02/17/2026 3:44 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/17/2026 3:46 PM | Clearmind Medicine (1892500) Filer | Form F-3 Registration statement for securities of certain foreign private issuers | |
| 02/17/2026 9:48 AM | Clearmind Medicine (1892500) Subject Iroquois Capital Management, LLC (1481867) Filed by | Form SCHEDULE 13G/A | |
| 02/11/2026 3:15 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/09/2026 7:19 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/06/2026 8:53 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/03/2026 7:06 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/01/2026 11:15 PM | Clearmind Medicine (1892500) Filer | Form EFFECT | |
| 02/01/2026 11:15 PM | Clearmind Medicine (1892500) Filer | Form EFFECT | |
| 02/01/2026 11:15 PM | Clearmind Medicine (1892500) Filer | Form EFFECT | |
| 01/27/2026 3:15 PM | Clearmind Medicine (1892500) Filer | Form POS AM | |
| 01/27/2026 3:15 PM | Clearmind Medicine (1892500) Filer | Form POS AM | |
| 01/27/2026 3:16 PM | Clearmind Medicine (1892500) Filer | Form POS AM | |
| 01/14/2026 8:00 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/31/2025 8:13 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Pentagon magnet restrictions take effect January 1, 2027 (Ad) A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production.
The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing.
The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027. Read the full breakdown of the proposed Army rare earth agreement and the company behind it. |
| 12/16/2025 7:50 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/12/2025 8:00 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/12/2025 5:35 AM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/10/2025 3:15 PM | Clearmind Medicine (1892500) Subject L.I.A. Pure Capital Ltd (1749628) Filed by | Form SCHEDULE 13G/A | |
| 12/10/2025 3:15 PM | Capitalink Ltd. (2036836) Filed by Clearmind Medicine (1892500) Subject | Form SCHEDULE 13G/A | |
| 12/10/2025 3:17 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/09/2025 11:15 PM | Clearmind Medicine (1892500) Filer | Form EFFECT | |
| 12/05/2025 4:02 PM | Clearmind Medicine (1892500) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/05/2025 3:52 PM | Clearmind Medicine (1892500) Filer | Form F-1/A | |